Groowe Groowe / Newsroom / QNTM
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

QNTM News

Quantum Biopharma Ltd. Class B Subordinate Voting Shares

Quantum BioPharma Provides Corporate Update

globenewswire.com
QNTM

Form 8-K

sec.gov
GRML GRMLW GRDX QNTM LIXT

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant

globenewswire.com
QNTM

Quantum Metric Named Most Valuable Pioneer in the QKS AI Maturity Matrix™: Product Analytics Software, 2026

prnewswire.com
QNTM

Quantum Metric's Record Sales Performance Signals the End of Dashboards for Digital Experience Analytics

globenewswire.com
QNTM

Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied

globenewswire.com
QNTM

Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis

globenewswire.com
QNTM

Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis

globenewswire.com
QNTM

Quantum Biopharma Provides Corporate Update

globenewswire.com
QNTM

Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status

globenewswire.com
QNTM